PT1264828E - Inibidor de uroquinase - Google Patents

Inibidor de uroquinase

Info

Publication number
PT1264828E
PT1264828E PT02016038T PT02016038T PT1264828E PT 1264828 E PT1264828 E PT 1264828E PT 02016038 T PT02016038 T PT 02016038T PT 02016038 T PT02016038 T PT 02016038T PT 1264828 E PT1264828 E PT 1264828E
Authority
PT
Portugal
Prior art keywords
optionally
alkyl
substituted
aryl
ring
Prior art date
Application number
PT02016038T
Other languages
English (en)
Inventor
Jorg Sturzebecher
John Foekens
Olaf Wilhelm
Viktor Magdolen
Verena Lutz
Original Assignee
Wilex Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8232314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1264828(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wilex Ag filed Critical Wilex Ag
Publication of PT1264828E publication Critical patent/PT1264828E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0404Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/041Heterocyclic compounds
    • A61K51/044Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205Radicals derived from carbonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
PT02016038T 1998-07-20 1999-07-20 Inibidor de uroquinase PT1264828E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP98113519 1998-07-20

Publications (1)

Publication Number Publication Date
PT1264828E true PT1264828E (pt) 2004-08-31

Family

ID=8232314

Family Applications (1)

Application Number Title Priority Date Filing Date
PT02016038T PT1264828E (pt) 1998-07-20 1999-07-20 Inibidor de uroquinase

Country Status (12)

Country Link
US (2) US6624169B1 (pt)
EP (2) EP1098651B1 (pt)
JP (1) JP4603162B2 (pt)
AT (2) ATE264103T1 (pt)
AU (1) AU754958B2 (pt)
BR (1) BR9912327B1 (pt)
CA (1) CA2338073C (pt)
DE (2) DE59909210D1 (pt)
ES (2) ES2189455T3 (pt)
MX (1) MXPA01000553A (pt)
PT (1) PT1264828E (pt)
WO (1) WO2000004954A2 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7745441B1 (en) * 1998-09-18 2010-06-29 Wilex Ag Urokinase inhibitors
DE10013715A1 (de) 2000-03-20 2001-09-27 Wilex Biotechnology Gmbh Hochselektive Inhibitoren des Urokinase-Plasminogenaktivators
DE10029014A1 (de) * 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
JP4414652B2 (ja) 2001-03-21 2010-02-10 ヴィレックス アクチェンゲゼルシャフト ウロキナーゼ阻害剤
AU2003219039A1 (en) 2002-03-11 2003-09-22 Curacyte Ag Urokinase inhibitors, production and use thereof
DE10225876A1 (de) * 2002-06-11 2003-12-24 Wilex Ag Guanidinophenylalaninverbindungen als Urokinase-Inhibitoren
DE10233632A1 (de) * 2002-07-24 2004-02-05 Wilex Ag Formulierungen von Phenylalanin-Derivaten
EP1525195A2 (de) * 2002-07-25 2005-04-27 Wilex AG Verfahren zur herstellung von phenylalanin-derivaten
DE10238048A1 (de) * 2002-07-25 2004-02-05 Wilex Ag Verfahren zur Herstellung von Phenylalanin-Derivaten
DE10301300B4 (de) 2003-01-15 2009-07-16 Curacyte Chemistry Gmbh Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein
DE10322191B4 (de) * 2003-05-16 2014-02-27 The Medicines Company (Leipzig) Gmbh N-sulfonylierte Aminosäurederivate, Verfahren zu ihrer Herstellung und ihre Verwendung
DE10323898A1 (de) 2003-05-26 2004-12-23 Wilex Ag Hydroxyamidin- und Hydroxyguanidin-Verbindungen als Urokinase-Hemmstoffe
DE10342108A1 (de) 2003-09-11 2005-04-14 Curacyte Chemistry Gmbh Basisch-substituierte Benzylaminanaloga als Inhibitoren des Gerinnungsfaktors Xa, ihre Herstellung und Verwendung
EP1637529A1 (en) * 2004-09-20 2006-03-22 4Sc Ag Novel piperidin-4-yl-thiazole-carboxamide analogues as inhibitors of T-cell proliferation and uses thereof
DE102004045720A1 (de) * 2004-09-21 2006-03-23 Wilex Ag Stabile Dosierungsform von Phenylalanin-Derivaten
WO2006136419A2 (en) 2005-06-24 2006-12-28 Wilex Ag Use of urokinase inhibitors for the treatment and/or prevention of neuropathological diseases
DE102006050672A1 (de) 2006-10-24 2008-04-30 Curacyte Discovery Gmbh Hemmstoffe des Plasmins und des Plasmakallikreins
JP2013528284A (ja) * 2010-05-26 2013-07-08 エクスプレッション、パソロジー、インコーポレイテッド ウロキナーゼ型プラスミノーゲン活性化因子タンパク質/プラスミノーゲン活性化因子阻害物質1型タンパク質選択反応モニタリングアッセイ
EP2590945B1 (en) 2010-07-07 2014-04-30 The Medicines Company (Leipzig) GmbH Serine protease inhibitors
KR102345773B1 (ko) 2015-03-30 2021-12-31 서니브룩 리서치 인스티튜트 암 치료 방법
TWI667228B (zh) * 2015-09-24 2019-08-01 南韓商Lg化學股份有限公司 化合物及含有該化合物的有機電子裝置
EP3359255A4 (en) * 2015-10-06 2019-06-12 Redhill Biopharma Ltd. POLYTHERAPIES FOR THE TREATMENT OF CANCER
CN117695284A (zh) 2020-03-10 2024-03-15 红山生物医药有限公司 冠状病毒感染的治疗
US11471448B2 (en) 2020-12-15 2022-10-18 Redhill Biopharma Ltd. Sphingosine kinase 2 inhibitor for treating coronavirus infection in moderately severe patients with pneumonia

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE460667B (sv) 1979-09-20 1989-11-06 Nippon Chemiphar Co Cyklohexankarboxylsyraderivat, foerfarande foer framstaellning daerav samt naemnda derivat foer terapeutisk anvaendning
EP0183271B1 (en) 1984-11-30 1990-05-16 Shosuke Okamoto Lysin derivative and proteinase inhibitor
CA2073776A1 (en) * 1990-11-15 1992-05-16 Joerg Stuerzebecher Meta-substituted phenyl alanine derivatives
WO1994018185A1 (de) * 1993-02-10 1994-08-18 Pentapharm Ag Piperazide von substituierten phenylalanin-derivativen als thrombin inhibitoren
US5550213A (en) 1993-12-27 1996-08-27 Rutgers, The State University Of New Jersey Inhibitors of urokinase plasminogen activator
AU3107795A (en) * 1994-08-09 1996-03-07 Pentapharm Ag Inhibitors of the benzamidine type
DE9418185U1 (de) * 1994-11-12 1995-02-23 Wolf Gmbh Richard Behälter für medizinische Instrumente
CH689611A5 (de) * 1995-03-01 1999-07-15 Pentapharm Ag Urokinase-Inhibitoren.
US7745441B1 (en) 1998-09-18 2010-06-29 Wilex Ag Urokinase inhibitors

Also Published As

Publication number Publication date
WO2000004954A2 (de) 2000-02-03
EP1098651A2 (de) 2001-05-16
ATE230599T1 (de) 2003-01-15
DE59909210D1 (de) 2004-05-19
AU754958B2 (en) 2002-11-28
DE59903981D1 (de) 2003-02-13
BR9912327B1 (pt) 2013-11-12
ES2219607T3 (es) 2004-12-01
EP1264828A1 (de) 2002-12-11
US20030013723A1 (en) 2003-01-16
BR9912327A (pt) 2001-05-02
WO2000004954A3 (de) 2000-06-22
CA2338073C (en) 2010-09-21
EP1264828B1 (de) 2004-04-14
EP1098651B1 (de) 2003-01-08
US6680320B2 (en) 2004-01-20
AU5161599A (en) 2000-02-14
CA2338073A1 (en) 2000-02-03
JP4603162B2 (ja) 2010-12-22
US6624169B1 (en) 2003-09-23
JP2002521348A (ja) 2002-07-16
ES2189455T3 (es) 2003-07-01
MXPA01000553A (es) 2002-04-24
ATE264103T1 (de) 2004-04-15

Similar Documents

Publication Publication Date Title
PT1264828E (pt) Inibidor de uroquinase
AU4437896A (en) Piperidine derivatives having tachykinin antagonist activity
HUT75113A (en) 4-substituted piperidine derivatives useful as neurokinin antagonists
DK436289D0 (da) Cycloalkyl-substituerede glutaramidderivater, farmaceutiske praeparater indeholdende disse forbindelser, forbindelserne til medicinsk anvendelse og deres anvendelse til fremstilling af laegemidler til behandling af hypertension, hjertesvigt eller renal insufficiens
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
EA200000110A1 (ru) Бициклические бензамиды производных 3- или 4-замещенного 4-(аминометил) пиперидина с гастрокинетическими свойствами
ATE319705T1 (de) Chinolyl-propylpiperidinderivate und deren verwendung als antimikrobielle wirkstoffe
YU32196A (sh) Upotreba jedinjenja za pripremanje leka korisnog za inhibiranje migracije vaskularnih ćelija glatkog mišića
NO306345B1 (no) Piperidin-derivater med PAF antagonist-aktivitet, anvendelse derav og farmasöytisk blanding
NO921831L (no) Indolderivater, fremgangsmaate for fremstilling derav samtpreparater inneholdende et slikt derivat
ATE150301T1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische zusammensetzungen davon zur prävention oder behandlung von herzerkrankungen
MX9306310A (es) Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
HUP0402515A2 (hu) Szubsztituált új N-[4-(1H-imidazol-1-il)-2-fluor-fenil]-3-(trifluor-metil)-1H-pirazol-5-karboxamidok Xa faktor inhibitorok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények
DK0506434T3 (da) Thiazolidinon- og oxazolidinon-derivater, fremstilling deraf og deres anvendelse som vasodilaterende midler
MX9304190A (es) Derivados novedosos de 4-[3-benzofuranil]piperidinilo y 4-[3-benzotientil]piperidinilo.
CO5280088A1 (es) Inhibidores de proteasa
YU67402A (sh) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
DE60120757D1 (de) 4-substituierte chinolone zur behandlung von autoimmunerkrankungen
NO953913D0 (no) Perhydroisoindolderivater, deres fremstilling samt farmasöytiske preparater inneholdende derivatene
DE60312511D1 (de) Oxophenylcyclohexylpropanolaminderivate, deren herstellung und verwendung in therapeutika
NZ533667A (en) Use of N-(indolecarbonyl)piperazine derivatives for treating obesity
MX9709468A (es) Composiciones farmaceuticas para minimizar la perdida osea.
DE69525548D1 (de) Substituierte 6-h-1,3,4,-thiadiazin-2-amine, deren verwendung als anaesthetisierende, cardiovaskulare und hypometabolische mittel, und eine sie enthaltende pharmazeutische zubereitung
HUP0402526A2 (hu) Vaszkuláris betegségek gyógyítására használható hidroxilaminszármazékok, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
TH47890A3 (th) สารยับยั้งเซรีนโปรทีเอส